Dr. Raje discusses how we can expect to see more drugs and new combinations utilized in the upfront setting, as approvals in the relapsed/refractory setting increase.

Dr. Kumar reviews a range of patient- and disease-related factors to consider when choosing therapies for NDMM including; transplant eligibility, renal function, and presence of extramedullary disease

Dr. Raje explores options for treating smoldering multiple myeloma and explains how approaches in this precursor state hope to prevent progression to myeloma.

In this video, Dr. McCarthy discusses whether it may become standard of care to use antibiotic prophylaxis in certain patients with multiple myeloma.

Dr. Raje explains where denosumab fits in the treatment profile for bone disease in multiple myeloma.

Dr. Kumar reviews what the 2018 approval of daratumumab in combination with the VMP regimen in certain newly diagnosed multiple myeloma patients means for ongoing developments in four-drug regimens.

Dr. McCarthy explains the specific risks that patients with smoldering myeloma face, and what you need to look for in follow-up monitoring.

Dr. Raje explains potential toxicities associated with the BCMA-directed CAR T-cell approach vs. transplant in multiple myeloma, highlighting the bb2121 clinical trial.

Dr. Cohen explains the impact of cytokine release syndrome and neurotoxicity when using BCMA-directed CAR-T cells.

Dr. Richardson briefly describes how the CD38-targeted monoclonal antibody isatuximab, if approved, may impact treatment selection for patients with relapsed/refractory multiple myeloma.